Vaccines

Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones including T helper cells for COVID-19, new gene found that could contribute to type 1 diabetes and more.
Earlier studies suggest a correlation between COVID-19 vaccines and menstrual changes. A new study says otherwise.
Scientists from Brigham and Women’s Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer’s disease.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
Between the numerous COVID-19 vaccines and several new antiviral drugs, it would appear that the tools to end the COVID-19 pandemic are within reach. Here’s a look at some of the top stories.
The total revenue for the quarter was $9.74 billion, a leap of 47%. The COVID-19 vaccine, Vaxzevria, only contributed 1% to the company’s profit.
Moderna responded to claims that the government should be co-patent owners of the mRNA vaccine developed by the company and said its mRNA sequence was exclusively selected by Moderna scientists.
The Bill & Melinda Gates Foundation is taking up the cause for pneumococcal infection with a $90 million investment in Seattle area’s Inventprise.
Scientists are conducting research into the possibility of creating a vaccine that activates T cells that targets not just SARS-CoV-2 but also its variations, even the ones that cause common colds.
PRESS RELEASES